Your browser doesn't support javascript.
loading
Implementation of a Novel Web-Based Lesion Selection Tool to Improve Acquisition of Tumor Biopsy Specimens.
Xu, Mingxuan; Tapia, Coya; Hajjar, Joud; Sabir, Sharjeel; Colen, Rivka; Nagarajan, Priyadharsini; Aung, Phyu P; Gong, Jing; Rodon, Jordi; Fu, Siqing; Stephen, Bettzy; Roy-Chowdhuri, Sinchita; Le, Hung; Yang, Vincent; Zarifa, Abdulrazzak; Abdelsalam, Mohamed Elsayed; Jhingran, Anuja; Javle, Milind; Pant, Shubham; Carter, Brett; Milton, Denai R; Sun, Ryan; Karp, Daniel D; Koay, Eugene Jon; Yang, Yali; Wistuba, Ignacio I; Hwu, Patrick; Meric-Bernstam, Funda; Naing, Aung.
Afiliação
  • Xu M; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Tapia C; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hajjar J; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Sabir S; Section of Immunology, Allergy and Rheumatology, Baylor College of Medicine and Texas Children's Hospital, Houston, TX, USA.
  • Colen R; Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Nagarajan P; Department of Diagnostic Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Aung PP; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Gong J; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Rodon J; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Fu S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Stephen B; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Roy-Chowdhuri S; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Le H; Department of Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Yang V; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Zarifa A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Abdelsalam ME; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Jhingran A; Department of Interventional Radiology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Javle M; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Pant S; Department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Carter B; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Milton DR; Section of Thoracic Imaging, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Sun R; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Karp DD; Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Koay EJ; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Yang Y; Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Wistuba II; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Hwu P; Department of Translational Molecular Pathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Meric-Bernstam F; Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
  • Naing A; Department of Investigational Cancer Therapeutics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
J Immunother Precis Oncol ; 4(2): 45-52, 2021 May.
Article em En | MEDLINE | ID: mdl-35663531
ABSTRACT

Introduction:

For maximum utility of molecular characterization by next-generation sequencing (NGS) and better understanding of tumor microenvironment with immune correlates analysis, biopsy specimens must yield adequate tumor tissue, and sequential biopsy specimens should sample a consistent site. We developed a web-based lesion selection tool (LST) that enables management and tracking of the biopsy specimen collections.

Methods:

Of 145 patients, the LST was used for 88 patients; the other 57 served as controls. We evaluated consistency of the lesion biopsied in longitudinal collections, number of cores obtained, and cores with adequate tumor cellularity for NGS. The Fisher exact test and Wilcoxon rank sum test were used to identify differences between the groups.

Results:

The analysis included 30 of 88 (34%) patients in the LST group and 52 of 57 (91%) in the control group. The LST workflow ensured 100% consistency in the lesions biopsied compared with 75% in the control group in longitudinal collections and increased the proportion of patients in whom at least five cores were collected per biopsy.

Conclusions:

The novel LST platform facilitates coordination, performance, and management of longitudinal biopsy specimens. Use of the LST enables sampling of the designated lesion consistently, which is likely to accurately inform us the effect of the treatment on tumor microenvironment and evolution of resistant pathways. Such studies are important translational component of any clinical trials and research as they guide the development of next line of therapy, which has significant effect on clinical utility. However, validation of this approach in a larger study is warranted.
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2021 Tipo de documento: Article